When warranted, ERBC conducts follow-up and supplemental safety pharmacology studies. These studies allow to investigate the mechanism of adverse effects suspected and/or observed through the core battery or the clinical trials programs and/or to evaluate potential adverse pharmacodynamic effects on organ system functions not addressed by the core battery or repeated dose toxicity studies.
Cardiovascular system
- Cardiac output
- Ventricular contractility
- Vascular resistance
- Effects of endogenous or exogenous substances on the cardiovascular responses
- …
Respiratory System
- Airway resistance
- Compliance
- Pulmonary arterial pressure
- Blood gases and blood pH
- …
Central Nervous System
- Behavioral pharmacology
- Learning and memory
- Ligand-specific binding
- Neurochemistry
- Visual, auditory and/or electrophysiology examinations
- …
Autonomic Nervous System
- Ligand-specific binding
- Functional response to agonists or antagonists
- …
Renal/Urinary system
- Diuresis, osmolality and pH in rat
- Fluid/electrolyte balance in rat
- Plasma proteins, cytology and blood chemistry in rat
- …
Gastrointestinal system
- Gastric secretion in rat
- Gastric damage (ulcerogenic potential in mouse)
- Gastrointestinal motility (charcoal meal propulsion in mouse)
- …
Other Organ Systems
- ERBC investigates on a routine basis the effects of new therapies on immune, endocrine and hepatic functions (including the appearance of liver damages).
